DavosPharma [ company website ]

We provide custom chemistry (novel raw materials, GMP intermediates, regulatory starting materials & APIs) and custom dosage forms (parenterals and orals), with supporting development, analytics, stability and regulatory documentation. We have successfully leveraged thirty-seven years of custom manufacturing experience, forming global strategic alliances with well-vetted, cGMP custom manufacturers in the EU, North America and Asia. Our expertise enables us to match your particular need with the supplier best able to deliver your project. Davos shares your risk by billing for deliverables, not best efforts, providing an additional level of assurance and oversight between you and the supplier.

Dipharma Group [ company website ]

Dipharma Group is highlighted on the market as one of the major European players in the field of Bulk Active Pharmaceutical Ingredients having a portfolio of about 60 APIs, with DMFs filed worldwide. We serve top ranking pharmaceutical companies in Europe, U.S.A. and Japan, supported by a fully equipped R&D Centre, consisting of more than 40 qualified researchers.

Modern laboratory equipment and one dedicated pilot plant enable us to develop and optimize complex chemical synthetic processes. Our three plants, operating in full cGMP, with a total capacity of about 550 m3, have been regularly inspected by US FDA through the years. All above competencies and capabilities make Dipharma the right partner for Custom Synthesis.

Our core technologies are Nitration, Nitroesterification, Azide Chemistry, High Pressure Hydrogenations, Chiral Synthesis, Organometallic Chemistry and Enzymatic Processes.

Domainex [ company website ]

Domainex is a fully integrated drug discovery service company based near Cambridge, UK serving pharmaceutical, biotechnology, academic and patient foundations globally. Domainex provides highly efficient and well considered scientific solutions to enable successful drug discovery programmes against a wide range of targets. Our highly experienced molecular biologists, medicinal, computation and analytical chemists have a strong success record in drug discovery, delivering on average one candidate drug every year for the past six years.

Dottikon [ company website ]

DOTTIKON EXCLUSIVE SYNTHESIS is specialized on hazardous chemistry, with a focus on strongly exothermic reactions as well as unstable, highly reactive, or high-potent compounds or mixtures. DOTTIKON ES manufactures high-quality intermediates and exclusive APIs, from the kilogram to the multi-ton range, for the world's leading pharmaceutical and chemical industries. Hazardous reactions often allow to shorten production and synthesic procedures, reduce waste, improve yields, selectivity, and purity, and therefore reduce overall costs. Among the core strengths of DOTTIKON ES are: hazardous reactions, such as reductions with complex hydrides, alkylations, azide chemistry, nitrations and oxidations. As well as heterogeneous and homogeneous catalytic hydrogenations, continuous reaction technologies and low temperature reactions.